Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.91 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.91 |
| ▸ | EGFR | P00533 | 4/20 | 0.91 |
| ▸ | KDR | P35968 | 4/20 | 0.91 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.91 |
| ▸ | LCK | P06239 | 2/20 | 0.91 |
| ▸ | LYN | P07948 | 2/20 | 0.91 |
| ▸ | RET | P07949 | 2/20 | 0.91 |
| ▸ | HCK | P08631 | 2/20 | 0.91 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.91 |
| ▸ | KIT | P10721 | 2/20 | 0.91 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.91 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.91 |
| ▸ | FLT3 | P36888 | 2/20 | 0.91 |
| ▸ | MST1R | Q04912 | 2/20 | 0.91 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.91 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.91 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.91 |
| ▸ | FYN | P06241 | 1/20 | 0.91 |
| ▸ | RAB6A | P20340 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489570 | 0.96 | AURKA (0.85) | AURKAAURKBEGFRKDRRIPK2 | |
| Barasertib SCHEMBL29720420 | 0.95 | AURKA (1.00) | AURKAAURKBEGFRKDRRIPK2 | |
| Barasertib SCHEMBL29368256 | 0.95 | AURKA (1.00) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL12132714 | 0.95 | AURKA (0.90) | AURKAAURKBEGFRKDRRIPK2 | |
| Barasertib SCHEMBL613582 | 0.95 | AURKA (1.00) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL1345874 | 0.95 | AURKA (0.85) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL12132713 | 0.95 | AURKA (0.92) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3862878 | 0.94 | AURKA (0.90) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3858181 | 0.94 | AURKA (0.89) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3490131 | 0.94 | AURKA (0.96) | AURKAAURKBEGFRKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-4242212-A2 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | Takeda Pharmaceutical Company Limited (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20230117295-A1 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-20 | — | — | US | disclosed |
| US-11584737-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| EP-3707151-B1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-20120220570-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120214795-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2471793-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471790-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471791-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471789-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2026808-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007132215-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | AURKA 2477/4885AURKB 1323/4885EGFR 4854/4885 |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | AURKA 35/4885AURKB 53/4885EGFR 3562/4885 |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | AURKA 3071/4885AURKB 1699/4885EGFR 1818/4885 |
| US-20230117295-A1 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | CDK1, CDK12, CDK15 | AURKA 62/4885AURKB 59/4885EGFR 1992/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | AURKA 3071/4885AURKB 1699/4885EGFR 1818/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | AURKA 3224/4885AURKB 2554/4885EGFR 865/4885 |
| US-11584737-B2 | Heterocyclic compound | CDK12, CDK1, CDK15 | AURKA 65/4885AURKB 60/4885EGFR 2135/4885 |
| US-20120214795-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | AURKA 959/4885AURKB 939/4885EGFR 1207/4885 |
| US-20120220570-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | AURKA 959/4885AURKB 939/4885EGFR 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.